Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease

被引:482
作者
Cooper-DeHoff, Rhonda M. [1 ,2 ]
Gong, Yan [1 ]
Handberg, Eileen M. [2 ]
Bavry, Anthony A. [2 ]
Denardo, Scott J. [2 ]
Bakris, George L. [3 ]
Pepine, Carl J. [2 ]
机构
[1] Univ Florida, Dept Pharmacotherapy & Translat Res, Coll Pharm, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Med, Div Cardiovasc Med, Gainesville, FL 32610 USA
[3] Univ Chicago, Pritzker Sch Med, Dept Med, Hypertens Dis Unit,Sec Endocrinol Diabet & Metab, Chicago, IL 60637 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2010年 / 304卷 / 01期
基金
美国国家卫生研究院;
关键词
VERAPAMIL SR-TRANDOLAPRIL; METAANALYSIS; ASSOCIATION; PREVENTION; MANAGEMENT; MORTALITY; INVEST;
D O I
10.1001/jama.2010.884
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Hypertension guidelines advocate treating systolic blood pressure (BP) to less than 130 mm Hg for patients with diabetes mellitus; however, data are lacking for the growing population who also have coronary artery disease (CAD). Objective To determine the association of systolic BP control achieved and adverse cardiovascular outcomes in a cohort of patients with diabetes and CAD. Design, Setting, and Patients Observational subgroup analysis of 6400 of the 22 576 participants in the International Verapamil SR-Trandolapril Study (INVEST). For this analysis, participants were at least 50 years old and had diabetes and CAD. Participants were recruited between September 1997 and December 2000 from 862 sites in 14 countries and were followed up through March 2003 with an extended follow-up through August 2008 through the National Death Index for US participants. Intervention Patients received first-line treatment of either a calcium antagonist or beta-blocker followed by angiotensin-converting enzyme inhibitor, a diuretic, or both to achieve systolic BP of less than 130 and diastolic BP of less than 85 mm Hg. Patients were categorized as having tight control if they could maintain their systolic BP at less than 130 mm Hg; usual control if it ranged from 130 mm Hg to less than 140 mm Hg; and uncontrolled if it was 140 mm Hg or higher. Main Outcome Measures Adverse cardiovascular outcomes, including the primary outcomes which was the first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke. Results During 16 893 patient-years of follow-up, 286 patients (12.7%) who maintained tight control, 249 (12.6%) who had usual control, and 431 (19.8%) who had uncontrolled systolic BP experienced a primary outcome event. Patients in the usual-control group had a cardiovascular event rate of 12.6% vs a 19.8% event rate for those in the uncontrolled group (adjusted hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.25-1.71; P<.001). However, little difference existed between those with usual control and those with tight control. Their respective event rates were 12.6% vs 12.7% (adjusted HR, 1.11; 95% CI, 0.93-1.32; P=.24). The all-cause mortality rate was 11.0% in the tight-control group vs 10.2% in the usual-control group (adjusted HR, 1.20; 95% CI, 0.99-1.45; P=.06); however, when extended follow-up was included, risk of all-cause mortality was 22.8% in the tight control vs 21.8% in the usual control group (adjusted HR, 1.15; 95% CI, 1.01-1.32; P=.04). Conclusion Tight control of systolic BP among patients with diabetes and CAD was not associated with improved cardiovascular outcomes compared with usual control.
引用
收藏
页码:61 / 68
页数:8
相关论文
共 27 条
  • [1] Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
    Adler, AI
    Stratton, IM
    Neil, HAW
    Yudkin, JS
    Matthews, DR
    Cull, CA
    Wright, AD
    Turner, RC
    Holman, RR
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258): : 412 - 419
  • [2] *AM DIAB ASS, 2002, DIABETES CARE S1, V25, pS85, DOI DOI 10.2337/DIACARE.25.2007.S85
  • [3] Amer Diabet Assoc, 2002, DIABETES CARE, V25, P213
  • [4] Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
  • [5] Amer Diabet Assoc, 2002, DIABETES CARE, V25, P199
  • [6] [Anonymous], 1984, ARCH INTERN MED, V144, P1045
  • [7] [Anonymous], 1993, ARCH INTERN MED, V153, P154, DOI DOI 10.1001/ARCHINTE.1993.00410020010002
  • [8] Clinical outcomes in the diabetes cohort of the international verapamil SR-Trandolapril study
    Bakris, GL
    Gaxiola, E
    Messerli, FH
    Mancia, G
    Erdine, S
    Cooper-DeHoff, R
    Pepine, CJ
    [J]. HYPERTENSION, 2004, 44 (05) : 637 - 642
  • [9] Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease Findings From the INternational VErapamil-SR/Trandolapril STudy
    Bavry, Anthony A.
    Anderson, R. David
    Gong, Yan
    Denardo, Scott J.
    Cooper-DeHoff, Rhonda M.
    Handberg, Eileen M.
    Pepine, Carl J.
    [J]. HYPERTENSION, 2010, 55 (01) : 48 - 53
  • [10] Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial
    Berl, T
    Hunsicker, LG
    Lewis, JB
    Pfeffer, MA
    Porush, JG
    Rouleau, JL
    Drury, PL
    Esmatjes, E
    Hricik, D
    Pohl, M
    Raz, I
    Vanhille, P
    Wiegmann, TB
    Wolfe, BM
    Locatelli, F
    Goldhaber, SZ
    Lewis, EJ
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07): : 2170 - 2179